Literature DB >> 21824111

Proteasome structure, function, and lessons learned from beta-lactone inhibitors.

Michael Groll1, Barbara C Potts.   

Abstract

The 26S proteasome is the enzymatic core engine of the ubiquitin and proteasome dependent proteolytic system (UPS), the major eukaryotic pathway for regulated protein degradation. The UPS plays a pivotal role in cellular protein turnover, protein quality control, antigen processing, signal transduction, cell cycle regulation, cell differentiation and apoptosis, inspiring in-depth studies of proteasome structure and function and the search for selective inhibitors. Structural studies revealed that the 26S proteasome comprises up to two 19S regulatory caps flanking a cylindrical 20S core particle, which houses the proteolytic subunits and is present in all kingdoms of life. This review highlights current understanding of 20S architecture, maturation and assembly, the mechanism for selective degradation of protein substrates targeted for destruction, and relationships to other proteases. This knowledge base has benefited from structurally diverse proteasome inhibitors discovered from unique sources, including terrestrial and marine actinomycetes that produce the β-lactone-γ- lactam superfamily of inhibitors, including omuralide, salinosporamide A (marizomib; NPI-0052) and the cinnabaramides. These "minimalist inhibitors" utilize dense functionality to maximum efficiency for potent and selective proteasome inhibition and have advanced from biochemical tools to potential agrochemicals and anticancer agents. In this review, lessons learned from the β-lactone-γ-lactam superfamily are presented, with an emphasis on their unique binding mechanisms elucidated through structural biology in concert with medicinal chemistry. Distinctions between slowly reversible and irreversible inhibitors are discussed, together with the relationship of irreversible binding at the molecular level to prolonged duration proteasome inhibition in tumor cells, and in vitro and in vivo efficacy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824111     DOI: 10.2174/156802611798281320

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  14 in total

Review 1.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

2.  Distinct Elements in the Proteasomal β5 Subunit Propeptide Required for Autocatalytic Processing and Proteasome Assembly.

Authors:  Xia Li; Yanjie Li; Cassandra S Arendt; Mark Hochstrasser
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 3.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

4.  Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.

Authors:  Doleshwar Niroula; Liam P Hallada; Camille Le Chapelain; Susantha K Ganegamage; Devon Dotson; Snezna Rogelj; Michael Groll; Rodolfo Tello-Aburto
Journal:  Eur J Med Chem       Date:  2018-08-20       Impact factor: 6.514

5.  Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.

Authors:  Theresa A Lansdell; Michelle A Hurchla; Jingyu Xiang; Stacy Hovde; Katherine N Weilbaecher; R William Henry; Jetze J Tepe
Journal:  ACS Chem Biol       Date:  2012-12-11       Impact factor: 5.100

6.  Global analysis of biosynthetic gene clusters reveals conserved and unique natural products in entomopathogenic nematode-symbiotic bacteria.

Authors:  Yi-Ming Shi; Merle Hirschmann; Yan-Ni Shi; Shabbir Ahmed; Desalegne Abebew; Nicholas J Tobias; Peter Grün; Jan J Crames; Laura Pöschel; Wolfgang Kuttenlochner; Christian Richter; Jennifer Herrmann; Rolf Müller; Aunchalee Thanwisai; Sacha J Pidot; Timothy P Stinear; Michael Groll; Yonggyun Kim; Helge B Bode
Journal:  Nat Chem       Date:  2022-04-25       Impact factor: 24.274

7.  Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.

Authors:  Andrzej Czerwinski; Channa Basava; Miroslawa Dauter; Zbigniew Dauter
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-02-07

8.  Bortezomib treatment causes long-term testicular dysfunction in young male mice.

Authors:  Mi Hou; Emma Eriksson; Konstantin Svechnikov; Kirsi Jahnukainen; Olle Söder; Andreas Meinhardt; Lars Sävendahl
Journal:  Mol Cancer       Date:  2014-06-20       Impact factor: 27.401

Review 9.  Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism.

Authors:  Srabani Pal; Ashish Bhattacharjee; Asif Ali; Narayan C Mandal; Subhash C Mandal; Mahadeb Pal
Journal:  J Inflamm (Lond)       Date:  2014-08-09       Impact factor: 4.981

Review 10.  Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective.

Authors:  Patrizia Russo; Alessandra Del Bufalo; Massimo Fini
Journal:  EXCLI J       Date:  2015-02-10       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.